Researchers in the cancer nanomedicine community debate whether use of nanoparticles can best deliver drug therapy to tumors passively – allowing the nanoparticles to diffuse into tumors and become held in place – or actively, by adding an anti-cancer molecule that would bind to specific cancer cell receptors and, in theory, keep the nanoparticles in the tumor longer. Now, researchers at the Johns Hopkins Kimmel Cancer Center have found that nanoparticles coated with trastuzumab, a drug sold under the name Herceptin that targets breast cancer cells, were better retained in tumors than plain nanoparticles. The researchers also found that immune cells exposed to nanoparticles induced an anti-cancer immune response by activating T cells, which invaded tumors and slowed tumor growth.
An official website of the United States government.